Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The primary objectives are a) to establish the maximum tolerated dose (MTD) of gemtuzumab
ozogamicin in combination with cytarabine and daunorubicin, and b) to assess the safety of
gemtuzumab ozogamicin when given concurrently with cytarabine and daunorubicin.